<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-63980</identifier>
<setSpec>1134-8046</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Neuropathic pain, a form of chronic pain caused by injury to or disease of the peripheral or central nervous system, is a formidable therapeutic challenge to clinicians because it does not respond well to traditional pain therapies. Significant improvement of neuropathic pain has been achieved with studies that have demonstrated efficacy of newer anticonvulsants in relieving this type of pain, by having a neuromodulatory effect on the hyperexcitable damaged nervous system. In recent years, several new-generation antiepileptic drugs have been introduced in clinical practice. Lamotrigine is a new antiepileptic drug that stabilizes neural membranes by blocking the activation of voltage-sensitive sodium channels and inhibiting the presynaptic release of glutamate. Full length reports have demonstrated the efficacy of lamotrigine in the treatment of various forms of neuropathic pain. The present drug profile provides a review of the pharmacologic properties of lamotrigine, the clinical evidence related to its efficacy and safety, in the treatment of neuropathic pain (AU)</dc:description>
<dc:creator>Sánchez-Montero, f. J</dc:creator>
<dc:creator>Santos, J. I</dc:creator>
<dc:creator>López-Correa, T</dc:creator>
<dc:creator>Vargas, M. C</dc:creator>
<dc:creator>Muriel, C</dc:creator>
<dc:creator>Doménech, B</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El dolor neuropático es una forma de dolor crónico provocada por una lesión o enfermedad del sistema nervioso, central o periférico. Dicho dolor supone un gran desafío, ya que habitualmente no responde a los tratamientos habituales. Una mejoría significativa se ha obtenido al tratar este tipo de dolor con fármacos anticonvulsivantes. Esta mejoría es debida al efecto neuromodulador de estos fármacos. En los últimos años se han introducido nuevos antiepilépticos en la práctica clínica. La lamotrigina es un nuevo fármaco antiepiléptico que estabiliza las membranas neuronales al bloquear los canales del sodio voltaje-dependiente e inhibir la liberación presináptica de glutamato. Diversos estudios han demostrado la eficacia de la lamotrigina en varias formas de dolor neuropático. Este trabajo aporta una revisión de la farmacología, de las evidencias clínicas de eficacia y de la seguridad de la lamotrigina en el tratamiento del dolor neuropático (AU)</dc:description>
<dc:source>Rev. Soc. Esp. Dolor;13(6): 410-420, ago.2006.</dc:source>
<dc:identifier>ibc-63980</dc:identifier>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d934^s22079</dc:subject>
<dc:subject>^d934^s22078</dc:subject>
<dc:subject>^d24718^s22057</dc:subject>
<dc:subject>^d9296^s22057</dc:subject>
<dc:subject>^d14676^s22057</dc:subject>
<dc:subject>^d9615^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9630^s22057</dc:subject>
<dc:subject>^d3952^s22057</dc:subject>
<dc:subject>^d934^s22020</dc:subject>
<dc:type>article</dc:type>
<dc:date>200608</dc:date>
</metadata>
</record>
</ibecs-document>
